Chemed Corporation’s Board of Directors has authorized an additional $300 million for share repurchases under its existing buyback program and has declared a quarterly cash dividend of $0.60 per share.
The repurchase authorization will be funded through a combination of operating cash flow and the company’s revolving credit facility, underscoring management’s confidence in Chemed’s cash‑generating ability. The $300 million authorization is part of a series of large buyback programs the company has pursued, including similar authorizations in November 2023 and August 2024.
The dividend of $0.60 per share is the 219th consecutive quarterly payment in Chemed’s 54‑year history. Shareholders of record as of February 23, 2026 will receive the dividend on March 13, 2026, and the amount matches the payment made in December 2025.
Chemed’s capital return decision comes at a time when the company maintains a strong cash position and no long‑term debt. The company’s two main subsidiaries—VITAS Healthcare and Roto‑Rooter—continue to generate robust operating cash flow, providing the liquidity needed for the buyback and dividend. Management’s choice to return capital rather than invest in new acquisitions or debt reduction signals confidence in the company’s core business and its ability to sustain cash flow in the near term.
Market analysts have noted a recent downgrade by Jefferies, which lowered Chemed’s rating from Buy to Hold and reduced its price target to $475 from $550, citing concerns about Roto‑Rooter’s margins. The capital return program, however, indicates that management remains optimistic about the company’s financial health and is prioritizing shareholder value in the current environment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.